US 12,448,378 B2
Fluoropyrrolopyridine compound and application thereof
Kun Fang, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to Wuxi Life Fountain Biotech Co., Ltd, Wuxi (CN)
Appl. No. 17/928,295
Filed by Wuxi Life Fountain Biotech Co., Ltd, Jiangsu (CN)
PCT Filed May 26, 2021, PCT No. PCT/CN2021/096143
§ 371(c)(1), (2) Date Nov. 29, 2022,
PCT Pub. No. WO2021/238999, PCT Pub. Date Dec. 2, 2021.
Claims priority of application No. 202010478432.9 (CN), filed on May 29, 2020; and application No. 202110139687.7 (CN), filed on Feb. 1, 2021.
Prior Publication US 2023/0212165 A1, Jul. 6, 2023
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01)] 12 Claims
 
1. A compound represented by formula (II) or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein,
ring A is

OG Complex Work Unit Chemistry
T1, T2, T3, T4 and T5 are each independently C, CH or N;
E1 is O or S;
R1 is each independently H or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Ra;
R2 is each independently H or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rb;
R3 is H or C1-3 alkyl;
R4 is each independently H, C1-3 alkyl, —O—C1-3 alkyl or —S(O)2—C1-3 alkyl, wherein the C1-3 alkyl, —O—C1-3 alkyl and —S(O)2—C1-3 alkyl are each independently optionally substituted with 1, 2 or 3 Rc;
Ra, Rb and Rc are each independently F, Cl, Br or I;
m is 1, 2 or 3.